Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

  1. Hailing Hsu*,
  2. David L. Lacey,
  3. Colin R. Dunstan,
  4. Irina Solovyev*,
  5. Anne Colombero*,
  6. Emma Timms*,
  7. Hong-Lin Tan,
  8. Gary Elliott*,
  9. Michael J. Kelley,
  10. Ildiko Sarosi,
  11. Ling Wang*,
  12. Xing-Zhong Xia*,
  13. Robin Elliott*,
  14. Laura Chiu*,
  15. Tabitha Black*,
  16. Sheila Scully,
  17. Casey Capparelli,
  18. Sean Morony,
  19. Grant Shimamoto§,
  20. Michael B. Bass, and
  21. William J. Boyle*,
  1. Departments of *Cell Biology, Pathology, Protein Chemistry, §Process Science, and Computational Biology, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799
  1. Communicated by David V. Goeddel, Tularik, Inc., South San Francisco, CA (received for review December 15, 1998)

Abstract

A receptor that mediates osteoprotegerin ligand (OPGL)-induced osteoclast differentiation and activation has been identified via genomic analysis of a primary osteoclast precursor cell cDNA library and is identical to the tumor necrosis factor receptor (TNFR) family member RANK. The RANK mRNA was highly expressed by isolated bone marrow-derived osteoclast progenitors and by mature osteoclasts in vivo. Recombinant OPGL binds specifically to RANK expressed by transfected cell lines and purified osteoclast progenitors. Transgenic mice expressing a soluble RANK-Fc fusion protein have severe osteopetrosis because of a reduction in osteoclasts, similar to OPG transgenic mice. Recombinant RANK-Fc binds with high affinity to OPGL in vitro and blocks osteoclast differentiation and activation in vitro and in vivo. Furthermore, polyclonal Ab against the RANK extracellular domain promotes osteoclastogenesis in bone marrow cultures suggesting that RANK activation mediates the effects of OPGL on the osteoclast pathway. These data indicate that OPGL-induced osteoclastogenesis is directly mediated through RANK on osteoclast precursor cells.

Footnotes

  • To whom reprint requests should be address. e-mail: bboyle{at}amgen.com.

  • ABBREVIATIONS:
    TNFR,
    tumor necrosis factor receptor;
    OPG,
    osteoprotegerin;
    OPGL,
    OPG ligand;
    CSF-1,
    colony-stimulating factor 1;
    JNK,
    Jun N-terminal kinase;
    PQCT,
    peripheral quantitative computerized tomography;
    TRAP,
    tartrate-resistant acid phosphatase;
    TRAF,
    TNFR-associated factor;
    RANK,
    receptor activator of NFκB
« Previous | Next Article »Table of Contents